Published in J Clin Invest on April 01, 1981
Role of complement and polymorphonuclear cells in demethylchlortetracycline-induced phototoxicity in guinea pigs. Inhibition by decomplementation in vivo. J Clin Invest (1983) 0.93
Activation of the complement system in patients with porphyrias after irradiation in vivo. J Clin Invest (1984) 0.83
Activation of factor XII-dependent pathways in human plasma by hematin and protoporphyrin. J Clin Invest (1985) 0.77
Activation of complement by 405-nm light in serum from porphyria cutanea tarda. Arch Dermatol Res (1985) 0.75
ANTIGEN-ANTIBODY CROSSED ELECTROPHORESIS. Anal Biochem (1965) 24.93
Penetration of epidermis by ultraviolet rays. Photochem Photobiol (1966) 1.90
Porphyria cutanea tarda. Clinical features and laboratory findings in 40 patients. Am J Med (1979) 1.65
A specific inhibitor of complement (C5)-derived chemotactic activity in serum from patients with systemic lupus erythematosus. J Clin Invest (1978) 1.28
Erythropoietic protoporphyria: lipid peroxidation and red cell membrane damage associated with photohemolysis. J Clin Invest (1972) 1.27
The complement system in necrotizing angiitis of the skin. Analysis of complement component activities in serum of patients with concomitant collagen-vascular diseases. J Invest Dermatol (1974) 1.24
Role of complement in porphyrin-induced photosensitivity. J Invest Dermatol (1981) 1.13
Cutaneous changes in the porphyrias. A microscopic study. Arch Dermatol (1973) 1.12
Inhibition of the alternative pathway of human complement in vitro by a natural microbial product, complestatin. J Immunol (1980) 1.09
Generation of chemotactic activity in serum from patients with erythropoietic protoporphyria and porphyria cutanea tarda. N Engl J Med (1981) 0.97
Erythropoietic protoprophyria--submicroscopic events during the acute photosensitivity flare. Br J Dermatol (1975) 0.96
Mouse model for protoporphyria. III. Experimental production of chronic erythropoietic protoporphyria-like skin lesions. J Invest Dermatol (1976) 0.92
Erythropoietic protoporphyria. Photoactivation of the complement system. J Clin Invest (1980) 0.85
Prosser White Oration 1978. The complement system in inflammation and host defence. Clin Exp Dermatol (1979) 0.84
Methods for the separation, purification and measurement of nine components of hemolytic complement in guinea-pig serum. Immunochemistry (1966) 15.12
Complement and immunoglobulins stimulate superoxide production by human leukocytes independently of phagocytosis. J Clin Invest (1975) 6.25
Complement dependent immune phagocytosis. I. Requirements for C'1, C'4, C'2, C'3. Exp Cell Res (1968) 6.20
Mechanisms of lysosomal enzyme release from leukocytes exposed to immune complexes and other particles. J Exp Med (1971) 3.38
Calcium-induced lysozyme secretion from human polymorphonuclear leukocytes. Biochem Biophys Res Commun (1974) 3.24
The stoichiometric measurement of the serum inhibition of the first component of complement by the inhibition of immune hemolysis. J Immunol (1968) 3.24
The unactivated form of the first component of human complement, C1. Biochem J (1976) 3.12
The complement system of man. I. N Engl J Med (1972) 3.09
Human C4-binding protein. II. Role in proteolysis of C4b by C3b-inactivator. J Exp Med (1978) 2.98
Evidence that the superoxide-generating system of human leukocytes is associated with the cell surface. J Clin Invest (1977) 2.77
Modulation of the classical pathway C3 convertase by plasma proteins C4 binding protein and C3b inactivator. Proc Natl Acad Sci U S A (1979) 2.73
Lysosomal enzyme release from human leukocytes: mediation by the alternate pathway of complement activation. J Immunol (1973) 2.66
The isolation and structure of C4, the fourth component of human complement. Biochem J (1977) 2.61
Human C4-binding protein. I. Isolation and characterization. J Exp Med (1978) 2.60
Targeted inhibition of calcineurin prevents agonist-induced cardiomyocyte hypertrophy. Proc Natl Acad Sci U S A (2000) 2.47
Calcineurin and human heart failure. Nat Med (1999) 2.41
Prevention of cardiac hypertrophy in mice by calcineurin inhibition. Science (1998) 2.39
Identification of a human cDNA encoding a functional high affinity lipoxin A4 receptor. J Exp Med (1994) 2.38
Control of autoimmune diabetes in NOD mice by GAD expression or suppression in beta cells. Science (1999) 2.19
Potassium and amino acid transport in human leukocytes exposed to phagocytic stimuli. J Cell Biol (1974) 2.16
A calcineurin-NFATc3-dependent pathway regulates skeletal muscle differentiation and slow myosin heavy-chain expression. Mol Cell Biol (2000) 2.16
Calcineurin promotes protein kinase C and c-Jun NH2-terminal kinase activation in the heart. Cross-talk between cardiac hypertrophic signaling pathways. J Biol Chem (2000) 2.12
Expression of chemokine receptors by subsets of neurons in the central nervous system. J Immunol (1997) 2.10
Langerhans cells: role in contact hypersensitivity and relationship to lymphoid dendritic cells and to macrophages. Immunol Rev (1980) 2.10
Interaction of plasma kallikrein with the C1 inhibitor. J Immunol (1970) 2.07
Pulmonary hypertension in systemic lupus erythematosus: report of four cases and review of the literature. Semin Arthritis Rheum (1981) 2.04
Generation of C5-derived lysosomal enzyme-releasing activity (C5a) by lysates of leukocyte lysosomes. J Immunol (1974) 2.02
Independent effects of IgG and complement upon human polymorphonuclear leukocyte function. J Immunol (1976) 1.97
Targeted inhibition of calcineurin attenuates cardiac hypertrophy in vivo. Proc Natl Acad Sci U S A (2001) 1.94
Mechanisms of lysosomal enzyme release from human polymorphonuclear leukocytes. Effects of phorbol myristate acetate. J Cell Biol (1975) 1.87
Localization of psoriasis-susceptibility locus PSORS1 to a 60-kb interval telomeric to HLA-C. Am J Hum Genet (2000) 1.86
Structural and functional differences between the H-2 controlled Ss and Slp proteins. J Exp Med (1978) 1.85
Ceruloplasmin. A scavenger of superoxide anion radicals. J Biol Chem (1979) 1.84
Calcineurin-mediated hypertrophy protects cardiomyocytes from apoptosis in vitro and in vivo: An apoptosis-independent model of dilated heart failure. Circ Res (2000) 1.82
Enhancement of random migration and chemotactic response of human leukocytes by ascorbic acid. J Clin Invest (1974) 1.81
Fluid phase destruction of C2hu by C1hu. II. Unmasking by C4ihu of C1hu specificity for C2hu. J Exp Med (1969) 1.78
The structure and enzymic activities of the C1r and C1s subcomponents of C1, the first component of human serum complement. Biochem J (1977) 1.78
Role of microtubule assembly in lysosomal enzyme secretion from human polymorphonuclear leukocytes. A reevaluation. J Cell Biol (1977) 1.69
Sudden blindness in acute pancreatitis. Possible role of complement-induced retinal leukoembolization. Arch Intern Med (1981) 1.62
Protected environments and prophylactic antibiotics. A prospective controlled study of their utility in the therapy of acute leukemia. N Engl J Med (1973) 1.61
Thromboxane generation by human peripheral blood polymorphonuclear leukocytes. J Exp Med (1978) 1.57
Modulation of function of the activated first component of complement by a fragment derived from serum. I. Effect on early components of complement. J Exp Med (1971) 1.54
Architectural organization of filiform papillae in normal and black hairy tongue epithelium: dissection of differentiation pathways in a complex human epithelium according to their patterns of keratin expression. Arch Dermatol (1999) 1.53
Staining of Langerhans cells with monoclonal antibodies to macrophages and lymphoid cells. Proc Natl Acad Sci U S A (1983) 1.50
Revised classification/nomenclature of vitiligo and related issues: the Vitiligo Global Issues Consensus Conference. Pigment Cell Melanoma Res (2012) 1.48
The complement system of man (second of four parts). N Engl J Med (1972) 1.47
Inhibition by epsilon-aminocaproic acid of the activation of the first component of the complement system. J Immunol (1975) 1.46
A neutrophil immobilizing factor derived from human leukocytes. II. Specificity of action on polymorphonuclear leukocyte mobility. J Immunol (1973) 1.45
Omega-oxidation is the major pathway for the catabolism of leukotriene B4 in human polymorphonuclear leukocytes. J Biol Chem (1984) 1.44
Enhancement of nitroblue tetrazolium dye reduction by leukocytes exposed to a component of complement in the absence of phagocytosis. J Immunol (1975) 1.43
Influence of divalent cations upon complement-mediated enzyme release from human polymorphonuclear leukocytes. J Immunol (1975) 1.43
The dual-specificity phosphatase MKP-1 limits the cardiac hypertrophic response in vitro and in vivo. Circ Res (2001) 1.43
Preconditioning provides complete protection against retinal ischemic injury in rats. Invest Ophthalmol Vis Sci (1998) 1.43
Hypertrophic defect unmasked by calcineurin expression in asymptomatic tropomodulin overexpressing transgenic mice. Cardiovasc Res (2000) 1.42
The complement system of man. 3. N Engl J Med (1972) 1.41
An abnormality of the gene that encodes neutrophil Fc receptor III in a patient with systemic lupus erythematosus. J Clin Invest (1990) 1.41
Altered erythrocyte C3b receptor expression, immune complexes, and complement activation in homosexual men in varying risk groups for acquired immune deficiency syndrome. J Clin Invest (1986) 1.40
Activation of the guinea pig alternative complement pathway by mouse IgA immune complexes. J Exp Med (1982) 1.39
Gastrointestinal "sterilization" in the treatment of patients with acute leukemia. Cancer (1970) 1.39
Action spectrum and response to antihistamine use in solar pruritus. Arch Dermatol (1999) 1.38
The complement system of man. 4. N Engl J Med (1972) 1.36
Influence of local anesthetics upon human polymorphonuclear leukocyte function in vitro. Reduction of lysosomal enzyme release and superoxide anion production. J Exp Med (1977) 1.36
Chemotactic responses of human peripheral blood monocytes to the complement-derived peptides C5a and C5a des Arg. J Immunol (1985) 1.30
Polyclonal antibody directed against human RANTES ameliorates disease in the Lewis rat adjuvant-induced arthritis model. J Clin Invest (1998) 1.30
A specific inhibitor of complement (C5)-derived chemotactic activity in serum from patients with systemic lupus erythematosus. J Clin Invest (1978) 1.28
Biologically active products of complement and acute lung injury in patients with the sepsis syndrome. Am Rev Respir Dis (1984) 1.28
Molecular basis for a polymorphism involving Fc receptor II on human monocytes. J Immunol (1989) 1.27
A single amino acid distinguishes the high-responder from the low-responder form of Fc receptor II on human monocytes. Eur J Immunol (1991) 1.26
The complement system in necrotizing angiitis of the skin. Analysis of complement component activities in serum of patients with concomitant collagen-vascular diseases. J Invest Dermatol (1974) 1.24
Vancomycin-induced vasculitis. South Med J (1986) 1.24
Phylogeny and function of the complement system. Annu Rev Microbiol (1971) 1.22
Sequences of complementary DNAs that encode the NA1 and NA2 forms of Fc receptor III on human neutrophils. J Clin Invest (1989) 1.22
Characterization of polymorphic forms of Fc receptor III on human neutrophils. J Clin Invest (1989) 1.21
Identification and characterization of a potent, selective, and orally active antagonist of the CC chemokine receptor-1. J Biol Chem (2000) 1.20
The interaction of human plasma fibronectin with a subunit of the first component of complement, C1q. J Immunol (1982) 1.18
Activation of complement by pathogenic and nonpathogenic Entamoeba histolytica. J Immunol (1986) 1.18
Leukotriene B4 omega-hydroxylase in human polymorphonuclear leukocytes. Partial purification and identification as a cytochrome P-450. J Clin Invest (1985) 1.15
Fluid phase destruction of C2hu by C1hu. I. Its enhancement and inhibition by homologous and heterologous C4. J Exp Med (1969) 1.15
Prostaglandin I2 is not a major metabolite of arachidonic acid in cultured endothelial cells from human foreskin microvessels. J Clin Invest (1984) 1.14
Chemotactic peptides modulate adherence of human polymorphonuclear leukocytes to monolayers of cultured endothelial cells. J Immunol (1986) 1.13
Endocytosis and shedding of the decay accelerating factor on human polymorphonuclear cells. J Immunol (1989) 1.13
Role of complement in porphyrin-induced photosensitivity. J Invest Dermatol (1981) 1.13
Leukotriene B4 omega-hydroxylase in human polymorphonuclear leukocytes. Suicidal inactivation by acetylenic fatty acids. J Biol Chem (1985) 1.12
Antiinflammatory effects of endotoxin. Inhibition of rabbit polymorphonuclear leukocyte responses to complement (C5)-derived peptides in vivo and in vitro. Am J Pathol (1983) 1.10
Nonphagocytic stimulation of human polymorphonuclear leukocytes: role of the plasma membrane. Semin Hematol (1979) 1.10
Endotoxin-induced selective dysfunction of rabbit polymorphonuclear leukocytes in response to endogenous chemotactic factors. Infect Immun (1985) 1.09
Urticaria and arthralgias as manifestations of necrotizing angiitis (vasculitis). J Invest Dermatol (1974) 1.09
Pathogenesis of dilated cardiomyopathy: molecular, structural, and population analyses in tropomodulin-overexpressing transgenic mice. Am J Pathol (1999) 1.09
Neutrophil degranulation. Contemp Top Immunobiol (1984) 1.09
Effect of steroids on lysosomes. Transplant Proc (1975) 1.08
Synexin-like proteins from human polymorphonuclear leukocytes. Identification and characterization of granule-aggregating and membrane-fusing activities. J Biol Chem (1987) 1.08
Cleavage of C3 by a neutral cysteine proteinase of Entamoeba histolytica. J Immunol (1989) 1.08
Two distinct cellular patterns in cutaneous necrotizing angiitis. J Invest Dermatol (1976) 1.07
Evidence of a role for mesothelial cell-derived interleukin 8 in the pathogenesis of asbestos-induced pleurisy in rabbits. J Clin Invest (1992) 1.07